[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

The Future of Probiotics (Part Two): Chronic Disease and Science Versus Regulation

February 2016 | 68 pages | ID: F677D2E6A9EEN
Euromonitor International Ltd

US$ 1,325.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Chronic diseases are going to create a new leverage point for probiotic products, especially in the area of cardiovascular health and diabetes. Part two of this global briefing on probiotics aims to highlight where future growth in probiotics is to be found. It also reviews the regulatory status and shows how both permitting and banning health claims can have a strong impact on the marketplace.

Euromonitor International's The Future of Probiotics (Part Two): Chronic Disease and Science Versus Regulation global briefing offers an insight into to the size and shape of the health and wellness marketplace, highlights buzz topics, emerging trends, categories and geographies as well as pressing industry issues and white spaces. It identifies the leading companies and brands, offers strategic analysis of key factors influencing wellbeing market - be they new product developments, packaging and ingredients innovations, introduction of new regulatory schemes, economic/lifestyle influences, distribution or retail pricing issues. Forecasts illustrate how the market is set to change and criteria for success.

Product coverage: Health and Wellness by Category, Health and Wellness by Prime Positioning, Health and Wellness by Type.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
  • Get a detailed picture of the Health and Wellness market;
  • Pinpoint growth sectors and identify factors driving change;
  • Understand the competitive environment, the market’s major players and leading brands;
  • Use five-year forecasts to assess how the market is predicted to develop.
Euromonitor International has over 40 years' experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago, Sydney, Tokyo and Bangalore and a network of over 800 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.
Introduction
The microbiome and chronic disease
Opportunities beyond chronic disease
The Regulatory environment
Outlook
Appendix


More Publications